A pharmaco-epidemiological study of psoriasis


  • Swikriti Gupta MBBS, K.S. Hegde Medical Academy, Deralakatte, Nitte Deemed to be University, Mangalore, Karnataka
  • Swathi Acharya Department of Pharmacolgy, K.S. Hegde Medical Academy, Deralakatte, Nitte Deemed to be University, Mangalore, Karnataka
  • Girisha Banavasi Shanmukha Department of Dermatology, K.S. Hegde Medical Academy, Deralakatte, Nitte Deemed to be University, Mangalore, Karnataka
  • Rajendra Holla Department of Pharmacolgy, K.S. Hegde Medical Academy, Deralakatte, Nitte Deemed to be University, Mangalore, Karnataka




Psoriasis, Glucocorticoid, Methotrexate, Psoriasis vulgaris


Background: Psoriasis is a chronic relapsing disease necessitates long-term therapy. The disease severity, comorbidities, and access to health care determine the choice of therapy for psoriasis. The main aim of the treatment of psoriasis is to induce prolonged remission and suppress the disease as there is no cure. It is only palliative and symptomatic treatment, and the choice of treatment modality is according to the type of presentation. The various modalities of treatment available include topical therapies, systemic therapies, phototherapy, and biologics. The difference includes among clinical varieties in their presenting features, severity, natural course, and response to the treatment are responsible for variation in choice of therapy.

Methods: In this descriptive study, data collected from patients diagnosed with psoriasis who were admitted in a K.S. Hegde Charitable hospital from January 2017 to January 2019 were analysed for demographic features, disease pattern and drug use pattern in patients.

Results: Psoriasis vulgaris/plaque type of psoriasis was commonly observed type of psoriasis in our patients with fourth and fifth decade patients getting more affected. Diabetes was the most commonly associated comorbid disorder. The patients were treated both with systemic and topical modalities of treatment, antihistaminic and methotrexate were most commonly most commonly used systemic drug and moisturizers and glucocorticoids were used topical drugs.

Conclusions: Psoriasis needs a multimodality treatment with careful monitoring for the comorbid disorder. Treatment choice is individualised depending on the severity and body parts affected.


Aryal S, Xian L J, Zhi G S, Karki J. Comparative Study Of The Efficacy Of Various Topical Treatment Modalities And Phototherapy For Psoriasis Vulgaris: A Review. Int J Sci Inv Today. 2017;6(5):570-7.

Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595-601

Jobling R. A patient’s journey. Psoriasis. Br Med J. 2007;334:953-4.

Lebwohl M, Ali S. Treatment of psoriasis. Part1: Topical Therapy and Phototherapy. J Am Acad Dermatol. 2001;45:487-98.

Paolo Gisondi, Anna Ferrazzi, Giampiero Girolomoni. Metabolic comorbidities and Psoriasis. Acta Dermatovenerol Croat. 2010;18(4):297-304.

Di Meglio P; Villanova F; Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4:6.

Harden, J.L.; Krueger, J.G.; Bowcock, A.M. The immunogenetics of psoriasis: A comprehensive review. J Autoimmun. 2015;64:66-73.

Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109,207-11.

Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica. 1974;148:1-18.

Ayanlowo O, Akinkugbe A. Clinical pattern of psoriasis in patients seen at a tertiary hospital in Nigeria. J Clin Sci. 2016;13:137-42.

Bhandary PR, Sanath PK, Shetty NJ, Girish PN, Lathika K. Clinico- epidemiological study of Psoriasis and associated comorbidities. IAIM, 2016;3(3):118-22.

Ramani Y R, Panigrahy B, Mishra S, Singh BTPS.A study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital. Indian J Basic Applied Med Res. 2016;5(3):116-22.

Bennett PN, Brown MJ. Clinical Pharmacology. 10th Edition. USA: Churchill Livingstone; 2008: 274-290.

Pavithran K, Karunakaran M, Palit A, Raghunatha S. Disorders of keratinization. In: Valia RG, Valia AR, editors. IADVL Textbook of Dermatology. 3rd Edition, Volume 1. Mumbai: Bhalani Publishing House; 2000: 1021-1056.

Karamata VV, Gandhi AM, Patel PP, Sutaria A, Desai MK. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life. Indian J Pharmacol. 2017;49(1):84-8.

Raghunandan R, Pundarikaksha HP, Gopal MG. Pattern of drug use in the management of psoriasis in a tertiary care hospital: a prospective study. Int J Basic Clin Pharmacol. 2014;3:611-8.

Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7:471-80.

Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272‑7.

Szepietowski JC, Reich A. Pruritus in psoriasis: An update. Eur J Pain. 2016;20:41‑6.

Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351‑75.

Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta‑analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014‑24.




How to Cite

Gupta, S., Acharya, S., Shanmukha, G. B., & Holla, R. (2019). A pharmaco-epidemiological study of psoriasis. International Journal of Basic & Clinical Pharmacology, 8(11), 2475–2479. https://doi.org/10.18203/2319-2003.ijbcp20194787



Original Research Articles